Trademark: 79143473
Word
THERAMETRICS
Status
Dead
Status Code
404
Status Date
Tuesday, November 21, 2023
Serial Number
79143473
Registration Number
4654777
Registration Date
Tuesday, December 16, 2014
Mark Type
4
Filing Date
Friday, November 22, 2013
Published for Opposition
Tuesday, September 30, 2014
Cancellation Date
Tuesday, November 21, 2023

Trademark Owner History
THERAMetrics holding AG - Original Registrant

Classifications
5 Pharmaceutical preparations for the treatment of cardiovascular and respiratory diseases, pulmonary fibrosis, sarcoidosis, lung disease, viral diseases, and infectious diseases; chemical preparations for sanitary purposes for medicine; pharmaceutical products for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, scleroderma, lupus erythematosus associated pulmonary hypertension, congenital systemic-to-pulmonary shunts associated pulmonary hypertension, portal hypertension associated pulmonary hypertension, HIV infection associated pulmonary hypertension, drugs and toxins associated pulmonary hypertension, glycogen storage disease associated pulmonary hypertension, Gaucher disease associated pulmonary hypertension, hereditary hemorrhagic telangiectasia associated pulmonary hypertension, hemoglobinopathies associated pulmonary hypertension, myeloproliferative disorders associated pulmonary hypertension, pulmonary veno-occlusive disease associated pulmonary hypertension, pulmonary capillary hemangiomatosis associated pulmonary hypertension, persistent pulmonary hypertension of the newborn, left-sided atrial or ventricular heart disease associated pulmonary hypertension, left-sided valvular heart disease associated pulmonary hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease, pulmonary hypertension associated with interstitial lung diseases, pulmonary hypertension associated with sleep disordered-breathing, pulmonary hypertension associated with alveolar hypoventilation disorders, pulmonary hypertension associated with chronic exposure to high altitude, pulmonary hypertension associated with developmental abnormalities, pulmonary hypertension due to chronic thrombotic and embolic diseases, pulmonary embolism due to tumor, parasites, foreign material, pulmonary hypertension associated with in situ thrombosis, pulmonary hypertension associated with sarcoidosis, pulmonary hypertension associated with histiocytosis X, pulmonary hypertension associated with lymphangiomatosis, pulmonary hypertension associated with sickle-cell disease, Eisenmenger syndrome, chronic fatigue syndrome, bronchial asthma, rheumatoid arthritis, lupus, Goodpasture's syndrome, Wegener's granulomatosis, type 1 diabetes mellitus, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, Guillain-Barre syndrome, Addison's disease, acute disseminated encephalomyelitis, antiphospholipid antibody syndrome, aplastic anemia, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, acute respiratory distress syndrome, acute lung injury, Hamman-Rich syndrome, idiopathic pulmonary fibrosis, bronchiolitis obliterans, hypersensitivity pneumonitis, lymphangiomyomatosis (LAM), usual interstitial pneumonia (UIP), Von Gierke syndrome, Osler-Weber-Rendu-Syndrome, small cell lung carcinoma, cystic fibrosis, tuberculosis, Hepatitis B virus infections, psoriasis, allergic dermatitis, scar keloids, pyogenic granulomas, blistering disease, Kaposi sarcoma in AIDS patients, systemic sclerosis, persistent hyperplastic vitreous syndrome, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, inflammatory bowel disease, periodontal disease, ascites, peritoneal adhesions, endometriosis, uterine bleeding, ovarian cysts, ovarian hyperstimulation, osteomyelitis, osteophyte formation, HIV-induced bone marrow angiogenesis, early diabetic nephropathy, cancer and malignancies and their metastases in numerous organs, hemangiomas, vasculitis, Sjögren's disease, DiGeorge syndrome, hereditary haemorrhagic telangiectasia, cavernous hemangioma, cutaneous hemangioma, lymphatic malformations, transplant arteriopathy, vascular anastomoses, adipose tissue in obesity, chronic allograft rejections; chemical preparations intended for healing, health care or medical and veterinary purposes, namely, chemical preparations for treating inflammatory, cardiovascular and respiratory diseases, pulmonary fibrosis, sarcoidosis, lung disease, viral diseases, and infectious diseases; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; radiological contrast substances for medical purposes; detergents for medical purposes; medicated mouth care and treatment preparations; medicated skin care preparations
42 Scientific research to order; conducting of research and development in the medical, pharmaceutical, pharmacological, biochemical and/or medical technology fields for others; conducting to order clinical studies and tests, namely, conducting clinical trials for others; assessment to order of scientific projects, namely, conducting scientific feasibility studies; scientific research consulting in the nature of evaluation to order of clinical studies and experiments; providing technical advice relating to operation of computers; providing scientific cooperations in the nature of providing scientific information in the field of pharmaceutical research; conducting scientific research projects in the medical, pharmaceutical, pharmacological, biochemical, and/or medical technology fields for others; scientific analysis laboratories
Color is not claimed as a feature of the mark.

Trademark Events
Mar 7, 2014
New Application Office Supplied Data Entered
Mar 10, 2014
Assigned To Examiner
Mar 14, 2014
Non-Final Action (Ib Refusal) Prepared For Review
Mar 14, 2014
Non-Final Action Mailed - Refusal Sent To Ib
Apr 4, 2014
Refusal Processed By Ib
Mar 6, 2014
Sn Assigned For Sect 66a Appl From Ib
Mar 11, 2014
Application Filing Receipt Mailed
Mar 13, 2014
Non-Final Action Written
Mar 14, 2014
Refusal Processed By Mpu
May 23, 2014
Teas Response To Office Action Received
Jun 5, 2014
Assigned To Lie
Jul 3, 2014
Final Refusal Written
Jul 3, 2014
Final Refusal E-Mailed
Jul 3, 2014
Notification Of Final Refusal Emailed
Aug 20, 2014
Teas Request For Reconsideration Received
Aug 20, 2014
Correspondence Received In Law Office
Aug 21, 2014
Teas/Email Correspondence Entered
Aug 22, 2014
Approved For Pub - Principal Register
Jun 10, 2014
Correspondence Received In Law Office
Jun 10, 2014
Teas/Email Correspondence Entered
Sep 10, 2014
Notification Of Notice Of Publication E-Mailed
Sep 30, 2014
Official Gazette Publication Confirmation E-Mailed
Dec 16, 2014
Registered-Principal Register
May 7, 2015
Final Disposition Notice Sent To Ib
Jun 12, 2015
Final Decision Transaction Processed By Ib
Aug 27, 2014
Law Office Publication Review Completed
Sep 30, 2014
Published For Opposition
Mar 16, 2015
Final Disposition Notice Created, To Be Sent To Ib
May 7, 2015
Final Disposition Processed
Dec 16, 2019
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Jul 7, 2022
Total Invalidation Of Reg Ext Protection Sent To Ib
Feb 10, 2020
Teas Change Of Correspondence Received
Jul 2, 2021
Cancelled Section 71
Mar 2, 2022
Total Invalidation Of Reg Ext Protection Created
Jul 7, 2022
Invalidation Processed
Jun 16, 2024
Death Of International Registration
Jun 16, 2024
Notification Of Effect Of Cancellation Of Intl Reg E-Mailed
Aug 8, 2022
Total Invalidation Processed By The Ib

Trademark Alertz updated from USPTO on 2030-01-24